Antibiotic resistance: The fate of all antibiotic monotherapies
Liz Meszaros, MDLinx
Superbugs and Superdrugs USA
Iselin, New Jersey, United States | November 13-14, 2017
Iselin, NJ, November 13, 2017--Is antibiotic resistance the fate of all antibiotic monotherapies?
According to John H. Rex, MD, FACP, chief medical officer, F2G Ltd., Manchester, UK, it is. Evolution and the lightning-fast reproductive cycles of bacteria make resistance inevitable, which have led to the current broken pipeline. The only recourse is to use the drugs available judiciously and effectively, consistently develop new ones, and to thoroughly explore and use alternatives such as vaccines and infection prevention.